Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

Bekaii-Saab, TS; Balser, S; Lohmann, R; Daoud, H; Liedert, B; Schliephake, D

Bekaii-Saab, TS (通讯作者)，Mayo Clin, Mayo Clin Hosp, Dept Internal Med, Canc Ctr, 5777E Mayo Blvd, Phoenix, AZ 85054 USA.

COLORECTAL CANCER, 2022; 11 (1):

Abstract

Aim: This study assessed the safety, efficacy, pharmacokinetics and immunogenicity of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索